You are here

Article Text

Article menu
Download PDFPDF
ePoster
EP503 Real world outcomes of advanced endometrial cancer treated with neoadjuvant chemotherapy
  1. K Baillie1,
  2. C Cunningham1,
  3. C Crearie1,
  4. J Laskey1,
  5. M Bennie2,3,
  6. K Burton4,
  7. A Sadozye1,
  8. R Lindsay4,
  9. R Harrand1,
  10. N Siddiqui4,
  11. N Reed1 and
  12. K Graham1
  1. 1Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde
  2. 2Strathclyde Institute for Pharmacy & Biomedical Sciences, University of Stracthclyde, Glasgow
  3. 3Public Health and Intelligence Strategic Business Unit, NHS National Services Scotland, Edinburgh
  4. 4Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, UK

Abstract

Introduction/Background Neoadjuvant chemotherapy (NACT) is increasingly used in locally advanced or selected stage 4B endometrial cancer that is considered unsuitable for primary surgery, despite the lack of randomised evidence. In the West of Scotland Cancer Network (WoSCAN), NACT is offered to women with inoperable locally advanced disease or limited stage 4B disease (omental/peritoneal involvement and/or small volume lung metastases/pleural effusion). This study aimed to identify the proportion of patients proceeding to delayed primary surgery or interval debulking surgery following NACT for endometrial cancer and evaluate survival outcomes.

Methodology Data were collected retrospectively from electronic clinical records of WoSCAN patients who commenced NACT between January 2012 and December 2016. Statistical analysis was performed using R®. OS was estimated using Kaplan-Meier method and Cox's proportional-hazards models used to calculate unadjusted hazard ratios (HR).

Results 54 patients were identified; median age was 67 years (range 36–85). All women had Stage III (57.4%) or IV (42.6%) disease. Pathological subtype consisted of serous (42.6%), endometrioid (31.5%), or other (25.9%). NACT regimen was almost exclusively Carboplatin/ Paclitaxel (92.6%); a median of 4 cycles were administered (range 1-6). 66.7% proceeded to surgery, 7.4% received primary (chemo)radiotherapy, and 25.9% received no definitive therapy. Of the 36 patients who underwent surgery, 83.3% received adjuvant radiotherapy. Data were censored in February 2018 at which time 33.3% were alive. Median OS was 31.12 months (95% CI 24.93–58.49); 40.8 months (95% CI 25.6 - Not reached) in the surgical cohort versus 18.6 months (95% CI 8.1–60.6) in patients who received NACT alone (HR 2.28 (95% CI 1.14–4.56)).

Conclusion 66.7% of women proceeded to surgery following NACT. Median OS is significantly improved with surgery compared to NACT alone. NACT is a valid option in patients with advanced endometrial cancer who are not suitable for primary surgery.

Disclosure Nothing to disclose.

http://dx.doi.org/10.1136/ijgc-2019-ESGO.561

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.